Orion Oyj (ORINY) Stock Price, News & Analysis

Company Overview

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Key Stats

• Today's Range: $25.54 to $26.70
• 50-Day Range: $21.95 to $26.70
• 52-Week Range: $17.50 to $28.55
• Volume: 25,487 shs
• Average Volume: 6,697 shs
• Market Capitalization: $7.54 billion
• P/E Ratio: 21.19
• Dividend Yield: 1.27%
• Price Target: N/A
• Consensus Rating: N/A

ORINY Stock Analysis - Frequently Asked Questions

How have ORINY shares performed this year?

Orion Oyj's stock was trading at $21.95 at the beginning of the year. Since then, ORINY shares have increased by 21.6% and is now trading at $26.70.
View the best growth stocks for 2025 here.

How were Orion Oyj's earnings last quarter?

Orion Oyj (OTCMKTS:ORINY) announced its earnings results on Tuesday, October, 29th. The company reported $0.63 earnings per share (EPS) for the quarter. The business had revenue of $517.97 million for the quarter. Orion Oyj had a trailing twelve-month return on equity of 39.49% and a net margin of 23.01%.

How do I buy shares of Orion Oyj?

Shares of ORINY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 11/7 Dividend: 10/16/2024
• Last Earnings: 10/29/2024
• Dividend Payable: 11/07/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ORINY
• Previous Symbol: NASDAQ:ORINY
• CUSIP: N/A
• CIK: N/A
• Web: www.orion.fi
• Phone: 358 10 4261
• Fax: N/A
• Employees: 3,632
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $1.26
• Trailing P/E Ratio: 21.19
• Forward P/E Ratio: 22.63
• P/E Growth: N/A
• Net Income: $234.64 million
• Net Margins: 23.01%
• Pretax Margin: 29.46%
• Return on Equity: 39.49%
• Return on Assets: 21.75%

Debt

• Debt-to-Equity Ratio: 0.25
• Current Ratio: 2.42
• Quick Ratio: 1.41

Sales & Book Value

• Annual Sales: $1.29 billion
• Price / Sales: 5.85
• Cash Flow: $1.08 per share
• Price / Cash Flow: 24.78
• Book Value: $3.41 per share
• Price / Book: 7.83

Miscellaneous

• Outstanding Shares: 282,270,000
• Free Float: N/A
• Market Cap: $7.54 billion
• Optionable: Not Optionable
• Beta: 0.23